Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02980484
Other study ID # 201603051
Secondary ID
Status Terminated
Phase Phase 2
First received February 25, 2016
Last updated March 26, 2018
Start date August 2016
Est. completion date August 2017

Study information

Verified date March 2018
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot study aims to investigate the efficacy of fMRI-targeted repetitive transcranial magnetic stimulation (rTMS) in treatment of major depression associated with traumatic brain injury (TBI). Half of patients will receive active treatment, while the other will receive a sham treatment with the option of receiving open-label active treatment afterwards.


Description:

rTMS is an FDA-approved treatment for major depressive disorder, but its utility has not yet been investigated for major depression associated with traumatic brain injury.

This will be a prospective double-blind randomized sham-controlled crossover study. Patients in the treatment group will receive 20 sessions of high-frequency rTMS over the left dorsolateral prefrontal cortex (DLPFC) and low-frequency rTMS over the right DLPFC. The DLPFC will be identified as target by using individual subject-level resting state network estimation (Hacker et al, 2013). Patients in the control group will receive 20 sham treatments designed to be visibly indistinguishable from active treatment, and will subsequently have the option to be crossed over to receive active treatment with the aforementioned protocol. A subgroup of patients in each group will receive more detailed diffusion imaging (diffusion tensor and diffusion kurtosis imaging) and resting state fMRI scans before and after the treatment in order to assess for changes in white matter integrity and functional connectivity associated with the treatment.


Recruitment information / eligibility

Status Terminated
Enrollment 15
Est. completion date August 2017
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion criteria:

- Adults age 18 to 65

- History of traumatic brain injury (TBI) at least two weeks prior to study initiation

- Presence of an active major depressive episode as defined by DSM-5 criteria, including depression secondary to traumatic brain injury

- Baseline score of 10 or greater on Montgomery-Asberg Depression Rating Scale (MADRS)

- Failure of at least one prior antidepressant trial after the traumatic brain injury

Exclusion criteria

History of:

- Moderate or severe substance use disorder in the past six months as defined by DSM-5 criteria, with the exception of cannabis and nicotine use disorders.

- Dementia, as defined by treating neurologist

- Moderate or severe autism spectrum disorder

- Bipolar disorder

- Schizophrenia spectrum disorders

Current evidence of:

- Substance-induced mood disorder

- Active psychotic symptoms

- Depression secondary to a general medical illness, with the exception of TBI

- Dysphoria better explained by a baseline personality disorder than a major depressive episode

- Dysphoria better explained by a baseline anxiety disorder (including post-traumatic stress disorder) rather than a major depressive episode

- Active suicidal ideation

Contraindications to rTMS treatment:

- Seizure disorder

- Significantly elevated seizure risk, as determined by clinician assessment

- TBI associated with elevated seizure risk, including penetrating injury and/or cortical intraparenchymal hemorrhage

- Presence of metallic objects within the head

- Presence of an implanted neurostimulation device within the head

Contraindications to MRI

- Severe claustrophobia

- Severe pain/illness exacerbated by lying prone in the scanner

- Presence of non-MRI compatible metal foreign bodies or implants

- Weight in excess of 350 lbs

- Shoulder width in excess of maximum tolerable width for scanner

Study Design


Intervention

Procedure:
Active
Repetitive transcranial magnetic stimulation (rTMS) will be applied to the left dorsolateral prefrontal cortex (DLPFC) (4000 pulses, 10 Hz, 5-sec trains, 25-sec inter-train interval) followed by the right DLPFC (1000 pulses, 1 Hz frequency, single train). The DLPFC will be identified using individual subject-level resting-state network estimation (Hacker et al, 2013). Each treatment will be completed over the course of 1 hour, and each subject will receive a total of 20 treatments over the course of 20 consecutive weekdays.
Sham
Treatment that looks and feels similar to active rTMS will be administered as a sham treatment.

Locations

Country Name City State
United States Washington University School of Medicine Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in depressive symptoms This will be measured as the mean percentage change in baseline scores on Montgomery-Asberg Depression Rating Scale (MADRS) before treatment and immediately after the 4-week treatment period. Difference between pre-treatment (baseline) and post-treatment (4 weeks)
Secondary Changes in resting-state fMRI and DTI findings MRI imaging will be conducted to assess resting-state functional connectivity using functional magnetic resonance imaging (fMRI). More detailed structural (DTI) and functional (fMRI) imaging will be measured in a subgroup of patients. Difference between pre-treatment (baseline) and post-treatment (4 weeks)
Secondary Changes in NIH Toolbox Cognitive, Emotional, and Quality of Life batteries The NIH Toolbox Cognitive battery will be used to determine change in cognitive symptoms with treatment. Emotional battery and TBI-QoL scales will be used to determine change in general neuropsychiatric symptom burden. Difference between pre-treatment (baseline) and post-treatment (4 weeks)
Secondary Changes in temperament and character Will administer the 140-question Temperament and Character Inventory (TCI-R140) before and after treatment. Difference between pre-treatment (baseline) and post-treatment (4 weeks)
Secondary Response and remission rates in depressive symptoms Percentage of subjects achieving response (>50% improvement in MADRS) and remission (final MADRS score <7) before treatment and immediately after the 4-week treatment period. Difference between pre-treatment (baseline) and post-treatment (4 weeks)
Secondary Changes in headache scales Mean percentage improvement in HIT-6 headache scores Difference between pre-treatment (baseline) and post-treatment (4 weeks)
Secondary Changes in tinnitus score Mean percentage improvement in tinnitus severity score and mini-Tinnitus Questionnaire scores Difference between pre-treatment (baseline) and post-treatment (4 weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A